Literature DB >> 20402555

Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature.

Michele Mancini1, Giampaolo Perna, Andrea Rossi, Antonino Petralia.   

Abstract

IMPORTANCE OF THE FIELD: Except for generalized anxiety disorder, few reports have been published on the efficacy, safety and tolerability of duloxetine in patients with anxiety disorders individually or in comorbidity with major depressive disorder (MDD). AREAS COVERED IN THIS REVIEW: The literature search in Medline (dating back to 1966) and Embase (dating back to 1988) databases was conducted using the OVID interface on 9 April 2009, restricted to any article or abstract in English, per title, reporting any information on the use of duloxetine in patients with any anxiety disorder with or without concomitant MDD. A systematic review approach was taken. WHAT THE READER WILL GAIN: The reader will gain knowledge of the current data available on the use of duloxetine to treat patients with anxiety disorders individually or in comorbidity with MDD. TAKE HOME MESSAGE: Duloxetine could be considered an effective treatment option in the treatment of anxiety disorders individually or in comorbidity with each other, or with MDD; however, apart from the well-demonstrated efficacy, tolerability and safety of duloxetine in the treatment of MDD with or without anxiety and GAD, data on this subject are preliminary and very limited, and more research is warranted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20402555     DOI: 10.1517/14656561003747441

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  8 in total

Review 1.  Generalised anxiety disorder.

Authors:  Christopher K Gale; Jane Millichamp
Journal:  BMJ Clin Evid       Date:  2011-10-27

2.  Drug-induced movement disorder and confusion associated with duloxetine.

Authors:  Sarah Hasan Siddiqui; Nadeem Ahmed Memon; Ravi Shanker
Journal:  BMJ Case Rep       Date:  2018-03-28

3.  Prevalence and predictors of anxiety in an African sample of recent stroke survivors.

Authors:  A Ojagbemi; M Owolabi; R Akinyemi; O Arulogun; J Akinyemi; O Akpa; F S Sarfo; E Uvere; R Saulson; S Hurst; B Ovbiagele
Journal:  Acta Neurol Scand       Date:  2017-04-17       Impact factor: 3.209

4.  Psychiatric Disorders Among Patients Seeking Treatment for Co-Occurring Chronic Pain and Opioid Use Disorder.

Authors:  Declan T Barry; Christopher J Cutter; Mark Beitel; Robert D Kerns; Christopher Liong; Richard S Schottenfeld
Journal:  J Clin Psychiatry       Date:  2016-10       Impact factor: 4.384

5.  Current diagnosis and treatment of anxiety disorders.

Authors:  Alexander Bystritsky; Sahib S Khalsa; Michael E Cameron; Jason Schiffman
Journal:  P T       Date:  2013-01

6.  Psychiatric comorbidity and order of condition onset among patients seeking treatment for chronic pain and opioid use disorder.

Authors:  Declan T Barry; Mark Beitel; Christopher J Cutter; David A Fiellin; Lynn M Madden; Nathan Lipkind; Pooja Bollampally; Christopher Liong; Richard S Schottenfeld
Journal:  Drug Alcohol Depend       Date:  2021-02-15       Impact factor: 4.492

7.  Duloxetine versus 'active' placebo, placebo or no intervention for major depressive disorder; a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.

Authors:  Faiza Siddiqui; Marija Barbateskovic; Sophie Juul; Kiran Kumar Katakam; Klaus Munkholm; Christian Gluud; Janus Christian Jakobsen
Journal:  Syst Rev       Date:  2021-06-09

8.  Proposing a new stroke-specific screening tool for depression: Examination of construct validity and reliability.

Authors:  Akin Ojagbemi; Mayowa Owolabi; Joshua Akinyemi; Bruce Ovbiagele
Journal:  eNeurologicalSci       Date:  2017-10-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.